Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Association of End-Tidal Carbon Dioxide Monitoring With Nurses' Confidence in Patient Readiness for Postanesthesia Discharge.

Zito A, Berardinelli A, Butler R, Morrison SL, Albert NM.

J Perianesth Nurs. 2019 Jun 7. pii: S1089-9472(19)30071-1. doi: 10.1016/j.jopan.2019.01.014. [Epub ahead of print]

PMID:
31182292
2.

Publisher Correction: Elastomeric sensor surfaces for high-throughput single-cell force cytometry.

Pushkarsky I, Tseng P, Black D, France B, Warfe L, Koziol-White CJ, Jester WF Jr, Trinh RK, Lin J, Scumpia PO, Morrison SL, Panettieri RA Jr, Damoiseaux R, Di Carlo D.

Nat Biomed Eng. 2018 Apr;2(4):265. doi: 10.1038/s41551-018-0207-0.

3.

Reusable Electroencephalography Electrodes: Variability in Cleaning and Reprocessing Practices.

Albert NM, Bena JF, Keleekai-Brapoh N, Rice K, Runner JC, Ciudad C, Morrison SL, Slifcak E.

Neurodiagn J. 2019;59(1):45-57. doi: 10.1080/21646821.2019.1571357.

PMID:
30916634
4.

An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1-HK2+ Multiple Myeloma.

Xu S, Zhou T, Doh HM, Trinh KR, Catapang A, Lee JT, Braas D, Bayley NA, Yamada RE, Vasuthasawat A, Sasine JP, Timmerman JM, Larson SM, Kim Y, MacLeod AR, Morrison SL, Herschman HR.

Cancer Res. 2019 May 15;79(10):2748-2760. doi: 10.1158/0008-5472.CAN-18-2799. Epub 2019 Mar 18.

PMID:
30885978
5.

Chemotherapy Safety: Reducing Errors With a Nurse-Led Time-Out Process.

Kalo K, Karius D, Bena JF, Morrison SL, Albert NM.

Clin J Oncol Nurs. 2019 Apr 1;23(2):197-202. doi: 10.1188/19.CJON.197-202.

PMID:
30880802
6.

Contamination of reusable electroencephalography electrodes: A multicenter study.

Albert NM, Bena JF, Ciudad C, Keleekai-Brapoh N, Morrison SL, Rice K, Slifcak E, Runner JC.

Am J Infect Control. 2018 Dec;46(12):1360-1364. doi: 10.1016/j.ajic.2018.05.021. Epub 2018 Jul 9.

PMID:
29997036
7.

Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.

Young PA, Yamada RE, Trinh KR, Vasuthasawat A, De Oliveira S, Yamada DH, Morrison SL, Timmerman JM.

J Interferon Cytokine Res. 2018 Jun;38(6):239-254. doi: 10.1089/jir.2018.0030.

8.

Factors Associated With Adherence to 14-Day Office Appointments After Heart Failure Discharge.

Distelhorst K, Claussen R, Dion K, Bena JF, Morrison SL, Walker D, Tai HL, Albert NM.

J Card Fail. 2018 Jun;24(6):407-411. doi: 10.1016/j.cardfail.2018.04.006. Epub 2018 Apr 25.

PMID:
29704619
9.

Nurses' decision making in heart failure management based on heart failure certification status.

Albert NM, Bena JF, Buxbaum D, Martensen L, Morrison SL, Prasun MA, Stamp KD.

Heart Lung. 2018 May - Jun;47(3):184-191. doi: 10.1016/j.hrtlng.2018.03.001. Epub 2018 Mar 29.

PMID:
29605089
10.

Pediatric Vascular Access Peripheral IV Algorithm Success Rate.

Hartman JH, Baker J, Bena JF, Morrison SL, Albert NM.

J Pediatr Nurs. 2018 Mar - Apr;39:1-6. doi: 10.1016/j.pedn.2017.12.002. Epub 2017 Dec 20.

PMID:
29525210
11.

Elastomeric sensor surfaces for high-throughput single-cell force cytometry.

Pushkarsky I, Tseng P, Black D, France B, Warfe L, Koziol-White CJ, Jester WF Jr, Trinh RK, Lin J, Scumpia PO, Morrison SL, Panettieri RA Jr, Damoiseaux R, Di Carlo D.

Nat Biomed Eng. 2018 Feb;2(2):124-137. doi: 10.1038/s41551-018-0193-2. Epub 2018 Feb 6. Erratum in: Nat Biomed Eng. 2018 Apr;2(4):265.

PMID:
31015629
12.

Functional Capacity but Not Early Uptake of Cardiac Rehabilitation Predicts Readmission in Patients With Metabolic Syndrome.

Siegmund LA, Albert NM, McClelland MS, Bena JF, Morrison SL.

J Cardiovasc Nurs. 2018 Jul/Aug;33(4):306-312. doi: 10.1097/JCN.0000000000000454.

PMID:
29303869
13.

Using the Vape Shop Standardized Tobacco Assessment for Retail Settings (V-STARS) to Assess Product Availability, Price Promotions, and Messaging in New Hampshire Vape Shop Retailers.

Kong AY, Eaddy JL, Morrison SL, Asbury D, Lindell KM, Ribisl KM.

Tob Regul Sci. 2017 Apr;3(2):174-182. doi: 10.18001/TRS.3.2.5. Epub 2017 Apr 1.

14.

Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer.

Li Z, Zhu Y, Li C, Trinh R, Ren X, Sun F, Wang Y, Shang P, Wang T, Wang M, Morrison SL, Zhang J.

Oncoimmunology. 2017 Feb 17;6(3):e1290038. doi: 10.1080/2162402X.2017.1290038. eCollection 2017.

15.

Clinical Nurse Specialist Roles in Conducting Research: Changes Over 3 Years.

Albert NM, Rice KL, Waldo MJ, Bena JF, Mayo AM, Morrison SL, Westlake C, Ellstrom K, Powers J, Foster J.

Clin Nurse Spec. 2016 Sep-Oct;30(5):292-301. doi: 10.1097/NUR.0000000000000236.

PMID:
27509566
16.

A Team Approach to Enhance Scholarship Among Honors Students in Nursing.

Jukkala AM, Miltner RS, Morrison SL, Gisiger-Camata S, Todd A, Moneyham LD, Meneses KM.

Nurs Educ Perspect. 2016 May-Jun;37(3):177-9.

PMID:
27405203
17.

Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.

Vasuthasawat A, Yoo EM, Trinh KR, Lichtenstein A, Timmerman JM, Morrison SL.

MAbs. 2016 Oct;8(7):1386-1397. Epub 2016 Jun 30.

18.

A comparative study of fluid management education before hospital discharge.

Rouse GW, Albert NM, Butler RS, Morrison SL, Forney J, Meyer J, Cary T, Kish G, Brosovich D.

Heart Lung. 2016 Jan-Feb;45(1):21-8. doi: 10.1016/j.hrtlng.2015.11.003.

PMID:
26702502
19.

Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.

Vega GG, Franco-Cea LA, Huerta-Yepez S, Mayani H, Morrison SL, Bonavida B, Vega MI.

Int J Oncol. 2015 Nov;47(5):1735-48. doi: 10.3892/ijo.2015.3170. Epub 2015 Sep 16.

20.

Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection.

Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, de la Torre JC, Nimmerjahn F, Brooks DG.

Immunity. 2015 Feb 17;42(2):379-390. doi: 10.1016/j.immuni.2015.01.005. Epub 2015 Feb 10.

21.

Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.

Valenzuela NM, Trinh KR, Mulder A, Morrison SL, Reed EF.

Am J Transplant. 2015 Jun;15(6):1502-18. doi: 10.1111/ajt.13174. Epub 2015 Feb 3.

22.

Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.

Young PA, Morrison SL, Timmerman JM.

Semin Oncol. 2014 Oct;41(5):623-36. doi: 10.1053/j.seminoncol.2014.08.002. Epub 2014 Aug 12. Review.

23.

Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

Yoo EM, Trinh KR, Tran D, Vasuthasawat A, Zhang J, Hoang B, Lichtenstein A, Morrison SL.

J Interferon Cytokine Res. 2015 Apr;35(4):281-91. doi: 10.1089/jir.2014.0125. Epub 2014 Oct 29.

24.

Redesigning the architecture of policy-making: Engaging with Māori on nanotechnology in New Zealand.

Munshi D, Kurian PA, Morrison T, Morrison SL.

Public Underst Sci. 2016 Apr;25(3):287-302. doi: 10.1177/0963662514548629. Epub 2014 Sep 5.

PMID:
25193966
25.

Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.

Trinh KR, Vasuthasawat A, Steward KK, Yamada RE, Timmerman JM, Morrison SL.

J Immunother. 2013 Jun;36(5):305-18. doi: 10.1097/CJI.0b013e3182993eb9.

26.
27.

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors.

De Oliveira SN, Wang J, Ryan C, Morrison SL, Kohn DB, Hollis RP.

J Transl Med. 2013 Jan 29;11:23. doi: 10.1186/1479-5876-11-23.

28.

Alcohol outlet density is related to police events and motor vehicle accidents in Manukau City, New Zealand.

Cameron MP, Cochrane W, McNeill K, Melbourne P, Morrison SL, Robertson N.

Aust N Z J Public Health. 2012 Dec;36(6):537-42. doi: 10.1111/j.1753-6405.2012.00935.x. Epub 2012 Nov 8.

PMID:
23216494
29.

Do patient and nurse outcome differences exist between 2 negative pressure wound therapy systems?

Albert NM, Rock R, Sammon MA, Bena JF, Morrison SL, Whitman A, Kato I, Landis-Erdman JC.

J Wound Ostomy Continence Nurs. 2012 May-Jun;39(3):259-66. doi: 10.1097/WON.0b013e3182487a50.

PMID:
22552107
30.

Efficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library.

Kim S, Kim YC, Qi H, Su K, Morrison SL, Chow SA.

Antimicrob Agents Chemother. 2011 Nov;55(11):5090-8. doi: 10.1128/AAC.00687-11. Epub 2011 Aug 29.

31.

In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways.

Mershon-Shier KL, Vasuthasawat A, Takahashi K, Morrison SL, Beenhouwer DO.

Mol Immunol. 2011 Sep;48(15-16):2009-18. doi: 10.1016/j.molimm.2011.06.215. Epub 2011 Jul 1.

32.

Characterization of IgA and IgM binding and internalization by surface-expressed human Fcα/μ receptor.

Yoo EM, Trinh KR, Lim H, Wims LA, Morrison SL.

Mol Immunol. 2011 Sep;48(15-16):1818-26. doi: 10.1016/j.molimm.2011.05.011. Epub 2011 May 31.

PMID:
21632111
33.

Differences in N-glycan structures found on recombinant IgA1 and IgA2 produced in murine myeloma and CHO cell lines.

Yoo EM, Yu LJ, Wims LA, Goldberg D, Morrison SL.

MAbs. 2010 May-Jun;2(3):320-34. Epub 2010 May 17.

34.

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.

Xuan C, Steward KK, Timmerman JM, Morrison SL.

Blood. 2010 Apr 8;115(14):2864-71. doi: 10.1182/blood-2009-10-250555. Epub 2010 Feb 4.

35.

Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT.

Afshar S, Olafsen T, Wu AM, Morrison SL.

J Exp Clin Cancer Res. 2009 Dec 3;28:147. doi: 10.1186/1756-9966-28-147.

36.

A rapid and economic in-house DNA purification method using glass syringe filters.

Kim YC, Morrison SL.

PLoS One. 2009 Nov 18;4(11):e7750. doi: 10.1371/journal.pone.0007750.

37.

Inhibitors of MyD88-dependent proinflammatory cytokine production identified utilizing a novel RNA interference screening approach.

Cho JS, Kim YC, Morrison SL.

PLoS One. 2009 Sep 15;4(9):e7029. doi: 10.1371/journal.pone.0007029.

38.

Transposon-directed base-exchange mutagenesis (TDEM): a novel method for multiple-nucleotide substitutions within a target gene.

Kim YC, Lee HS, Yoon S, Morrison SL.

Biotechniques. 2009 Jun;46(7):534-42. doi: 10.2144/000113152.

39.
40.

Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer.

Afshar S, Asai T, Morrison SL.

Mol Cancer Ther. 2009 Jan;8(1):185-93. doi: 10.1158/1535-7163.MCT-08-0652.

41.

Role of complement in protection against Cryptococcus gattii infection.

Mershon KL, Vasuthasawat A, Lawson GW, Morrison SL, Beenhouwer DO.

Infect Immun. 2009 Mar;77(3):1061-70. doi: 10.1128/IAI.01119-08. Epub 2008 Dec 29.

42.

N-terminal domain-deleted mu transposase exhibits increased transposition activity with low target site preference in modified buffers.

Kim YC, Morrison SL.

J Mol Microbiol Biotechnol. 2009;17(1):30-40. doi: 10.1159/000178019. Epub 2008 Nov 25.

PMID:
19033677
43.

Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity.

Cho JS, Hsu JV, Morrison SL.

Cancer Immunol Immunother. 2009 Jul;58(7):1057-69. doi: 10.1007/s00262-008-0622-2. Epub 2008 Nov 19.

44.

Antibody-fused interferons as an effective approach to enhance target specificity and antiviral efficacy of type I interferons.

Cheng LS, Hwang S, Huang TH, Sheu TC, Sun R, Morrison SL, Cheng G, Shahangian A.

Cell Res. 2008 Dec;18(12):1230-2. doi: 10.1038/cr.2008.304. No abstract available.

PMID:
19002159
45.

Recombinant polymeric IgG anti-Rh: a novel strategy for development of direct agglutinating reagents.

Montano RF, Penichet ML, Blackall DP, Morrison SL, Chintalacharuvu KR.

J Immunol Methods. 2009 Jan 1;340(1):1-10. doi: 10.1016/j.jim.2008.09.011. Epub 2008 Oct 9.

PMID:
18848836
46.

Cloning, expression, and modification of antibody V regions.

Morrison SL.

Curr Protoc Immunol. 2002 May;Chapter 2:Unit 2.12. doi: 10.1002/0471142735.im0212s47.

PMID:
18432877
47.

Double-stranded DNA sequence analysis.

Morrison SL.

Curr Protoc Immunol. 2001 May;Chapter 10:Unit 10.25. doi: 10.1002/0471142735.im1025s14. Review.

PMID:
18432690
48.

Transfection of lymphoid cells.

Morrison SL.

Curr Protoc Immunol. 2001 May;Chapter 10:Unit 10.17B. doi: 10.1002/0471142735.im1017bs31. Review.

PMID:
18432681
49.

Transformation of E. coli by electroporation.

Morrison SL.

Curr Protoc Immunol. 2001 May;Appendix 3:Appendix 3N. doi: 10.1002/0471142735.ima03ns21.

PMID:
18432665
50.

Preparing frozen bacterial stocks.

Morrison SL.

Curr Protoc Immunol. 2001 May;Appendix 3:Appendix 3M. doi: 10.1002/0471142735.ima03ms21.

PMID:
18432664

Supplemental Content

Loading ...
Support Center